Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.3
5.5
Journals
Biomolecules
Special Issues
Advances in Ginsenosides 2.0
share announcement

Advances in Ginsenosides 2.0

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Natural and Bio-inspired Molecules".

Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 5596

Special Issue Editor

Prof. Dr. Jen-Tsung Chen

E-Mail Website
Guest Editor
Department of Life Sciences, National University of Kaohsiung, Kaohsiung 811, Taiwan
Interests: bioactive compounds; chromatography techniques; medicinal plants; phytochemicals; plant biotechnology; plant growth regulators; plant secondary metabolites
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue is a continuation of the previous Special Issue “Advances in Ginsenosides”.

Ginsenosides, also known as ginseng saponins or triterpene saponins, are the foremost bioactive constituents of ginseng, which belongs to the genus Panax. The genus name Panax means “all-curing” in Greek, and Panax ginseng C. A. Meyer has been used as a top-grade herb in traditional Chinese medicine and the king of tonic herbs for over 2000 years in oriental countries. Ginseng preparations have a wide range of benefits for human health, including enhancing immune function, improving circulation and vascular function, preventing neurological diseases, modulating metabolism, and improving vitality and health. Ginsenosides are unique to ginseng species, more than 100 ginsenosides have been identified. Ginsenosides have a variety of biological activities, such as neuroprotection, antioxidation, anticancer, antistress, anti-inflammatory, antiaging, antifatigue, cytotoxicity, inhibiting cell apoptosis, and inhibiting platelet aggregation. Recent studies on the therapeutic potential of ginsenosides have revealed the molecular mechanisms of action against cardiovascular diseases, immune-system diseases, and nervous system diseases, as well as their anti-inflammatory activity and modulation of the endocrine system. In brief, ginsenosides possess complicated bioactive effects and regulate multiple metabolic pathways; therefore, their efficacy is interconnected and difficult to clarify.

 

This Special Issue aims to integrate recent innovative approaches and attempts to make significant progress in the biochemistry of ginsenosides by expanding knowledge on a wide range of topics, including biotechnology, biosynthetic machinery, pharmacological studies, and the application of high-throughput technologies such as genomics, transcriptomics, proteomics, metabolomics, and bioinformatics and other related topics. I sincerely invite scientists to contribute both original research articles and reviews on this Special Issue.

 

Dr. Jen-Tsung Chen
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • ginseng
  • ginsenosides
  • pharmacology
  • multi-omics
  • high-throughput technologies

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

16 pages, 2158 KiB  
Article
Concomitant Administration of Red Ginseng Extract with Lactic Acid Bacteria Increases the Plasma Concentration of Deglycosylated Ginsenosides in Healthy Human Subjects
by Ji-Hyeon Jeon, Jin-Hyang Park, So Yeon Jeon, Minyeong Pang, Min-Koo Choi and Im-Sook Song
Biomolecules 2022, 12(12), 1896; https://0-doi-org.brum.beds.ac.uk/10.3390/biom12121896 - 17 Dec 2022
Cited by 3 | Viewed by 1557
Abstract
With the increased frequency of red ginseng extract (RGE) and lactic acid bacteria (LAB) co-administration, we aimed to investigate the interactions between RGE and LAB with regard to in vitro and in vivo deglycosylation metabolism and the pharmacokinetics of ginsenosides. As a proof-of-concept [...] Read more.
With the increased frequency of red ginseng extract (RGE) and lactic acid bacteria (LAB) co-administration, we aimed to investigate the interactions between RGE and LAB with regard to in vitro and in vivo deglycosylation metabolism and the pharmacokinetics of ginsenosides. As a proof-of-concept study, five healthy humans were administered RGE (104.1 mg of total ginsenosides/day) with or without co-administration of LAB (2 g, 1 billion CFU/day) for 2 weeks, and the plasma concentrations of ginsenosides in human plasma were monitored. The plasma exposure to compound K (CK), ginsenoside Rh2 (GRh2), protopanaxadiol (PPD), and protopanaxatriol (PPT) in the concomitant administration RGE and LAB groups increased by 2.7-, 2.1-, 1.6-, and 3.5-fold, respectively, compared to those in the RGE administration group, without a significant change in Tmax. The plasma concentrations of GRb1, GRb2, and GRc remained unchanged, whereas the AUC values of GRd and GRg3 significantly decreased in the concomitant administration RGE and LAB groups. To understand the underlying mechanism, the in vitro metabolic activity of ginsenosides was measured during the fermentation of RGE or individual ginsenosides in the presence of LAB for 1 week. Consistent with the in vivo results, co-incubation with RGE and LAB significantly increased the formation rate of GRh2, CK, PPD, and PPT. These results may be attributed to the facilitated deglycosylation of GRd and GRg3 and the increased production of GRh2, CK, PPD, and PPT by the co-administration of LAB and RGE. In conclusion, LAB supplementation increased the plasma concentrations of deglycosylated ginsenosides, such as GRh2, CK, PPD, and PPT, through facilitated deglycosylation metabolism of ginsenosides in the intestine. Full article
(This article belongs to the Special Issue Advances in Ginsenosides 2.0)
►▼ Show Figures

Figure 1

Review

Jump to: Research

28 pages, 2835 KiB  
Review
Ginsenoside and Its Therapeutic Potential for Cognitive Impairment
by Hui Feng, Mei Xue, Hao Deng, Shiqi Cheng, Yue Hu and Chunxiang Zhou
Biomolecules 2022, 12(9), 1310; https://0-doi-org.brum.beds.ac.uk/10.3390/biom12091310 - 16 Sep 2022
Cited by 19 | Viewed by 3388
Abstract
Cognitive impairment (CI) is one of the major clinical features of many neurodegenerative diseases. It can be aging-related or even appear in non-central nerve system (CNS) diseases. CI has a wide spectrum that ranges from the cognitive complaint with normal screening tests to [...] Read more.
Cognitive impairment (CI) is one of the major clinical features of many neurodegenerative diseases. It can be aging-related or even appear in non-central nerve system (CNS) diseases. CI has a wide spectrum that ranges from the cognitive complaint with normal screening tests to mild CI and, at its end, dementia. Ginsenosides, agents extracted from a key Chinese herbal medicine (ginseng), show great promise as a new therapeutic option for treating CI. This review covered both clinical trials and preclinical studies to summarize the possible mechanisms of how ginsenosides affect CI in different diseases. It shows that ginsenosides can modulate signaling pathways associated with oxidative stress, apoptosis, inflammation, synaptic plasticity, and neurogenesis. The involved signaling pathways mainly include the PI3K/Akt, CREB/BDNF, Keap1/Nrf2 signaling, and NF-κB/NLRP3 inflammasome pathways. We hope to provide a theoretical basis for the treatment of CI for related diseases by ginsenosides. Full article
(This article belongs to the Special Issue Advances in Ginsenosides 2.0)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop